thursday morn offici round viral load test menu
unit state fda pma approv aptima hbv assay third
final viral load approv compani follow fda approv
hcv one broadest us molecular menu
industri believ panther mdx workflow prime posit
aggreg share consolid lab industri market leader sexual
health test market share approach billion mdx segment
dilig interact lab director believ panther competit
advantag includ low cost assay autom random-access workflow low
hands-on time abil reach scale mid-to-high throughput test
believ leverag panther strength gain share viral load
open roughli million test opportun compani viral
load approv follow fall expans panther pcr-base test
fusion sidecar ad respiratori ldt menu instrument
complet menu allow custom consolid test onto
panther platform expand system address market opportun fold
factor togeth high convict abil drive mid-
singl digit growth overal diagnost segment rev import
growth driver compani reiter overweight rate
observ panther mdx platform one broadest menu
approv viral load approv improv convict
sustain growth diagnost franchis viral load market
current domin roch share abbott market concentr
make difficult displac incumb believ panther perform
characterist larg instal base give opportun take share
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ grow
stronger longer driven longer
mammographi tail mdx growth panther
myosur tuck-in new product launch
could drive modest upsid revenu
mdx gyn surgic busi continu
drive outsiz growth new product launch
add modestli growth upsid case
reflect upsid earn power
penetr rate us mammographi
busi slow faster expect downsid
case reflect downsid earn
power
thursday morn offici round viral load test menu unit
state fda pma approv aptima hbv assay third final viral
load approv compani follow fda approv hcv
one broadest us molecular menu industri
believ panther mdx workflow prime posit aggreg share
consolid lab industri market leader sexual health test
market share approach billion mdx segment dilig
interact lab director believ panther competit advantag includ low
cost assay autom random-access workflow low hands-on time abil
reach scale mid-to-high throughput test believ leverag
panther strength gain share viral load open roughli million
test opportun compani viral load approv follow fall expans
panther pcr-base test fusion sidecar ad respiratori ldt
menu instrument complet menu allow custom
consolid test onto panther platform expand system address market
opportun fold factor togeth high convict abil
drive mid-singl digit growth overal diagnost segment rev
import growth driver compani reiter overweight rate
panther mdx platform one broadest menu approv
 recent launch viral load assay europ believ
abl leverag instal base improv custom util
addit expand util believ compani abl drive increment
panther placement expans menu
panther diagnost instrument place primarili use women
health test today panther system menu origin women categori
market leader ct/ng test million annual sale
hpv million grow rapidli trichomona million
continu favor amongst peer molecular test view panther
system best-in-bre mid-to-high throughput test panther system featur
high-throughput result signific autom low-cost assay aptima
portfolio panther oper proprietari tma chemistri provid
qualiti metric similar pcr consid gold standard work realli well
tough sampl type differenti look sexual health viral load categori
launch panther fusion expand menu pcr-
base respiratori test believ addit viral load respiratori assay
essenti tripl compani address market billion billion
believ expans viral load test import implic
competit dynam us molecular diagnost landscap market
leader sexual health test follow roch abbott roch market leader
viral load test follow abbott new entrant interact
lab director weve heard demand consolid test within lab onto fewer
platform believ open new opportun market
exampl mani lab today run viral load test roch abbott system
run sexual health assay holog panther recent approv believ
could gain first mover advantag could help compani take
share viral load market
viral load approv improv convict sustain growth
holog diagnost franchis expect contribut assay
addit growth adopt curv like modest contribut growth
number year laboratori gener sign year contract supplier
address opportun limit begin launch addit given
complex assay requir pma approv valid process last
sever month dont anticip major contribut assay
expect revenu ramp beyond holog guidanc
embed mid-singl digit growth diagnost segment believ assum
high-singl digit trend molecular flattish growth cytology/perinat viral
load launch improv visibl hit high-singl digit molecular
target
growth mdx
sexual healthvir loadrespiratorytransplantationhaicompanion dxcompanyinstrumentlaunchs placedsampl per shiftct/nghpvhsv a/b/rsvadv/hmpv/rvparaflucmvebvhsvvzvbkvc cyclerallallallallamplicor ampliprepallallallallcoba indic fda pma approvaleu indic ce-ivd approvalal indic us euro growthpanth instal basepanth instal basemdx growth barclay holog inc
market viral load test current domin roch estim
market share abbott market concentr make difficult
displac incumb believ panther perform characterist larg
instal base give opportun take share join short list
competitor includ siemen uncov cepheid uncov stack
rel competit panther platform competit
mid-to-high throughput custom throughput test per hour shift
rel modest footprint yield placement count around today roch
first market viral load test earn origin approv amplicor
platform recent roch receiv fda approv viral load menu
coba high-throughput analyz see chart virolog
growth driver roch repres million busi
weaker recent result driven difficult comp result hcv drug
util hard imagin becom market leader
virolog believ line-of-sight compani becom secondari
takeaway
recent lab director
survey pleas see report
januari lab
interest pama-driven
viral load takeaway barclay lab director
late novemb perform survey lab director purchas trend
across import test categori coverag focu
perspect compani expect gain lose share next year
respond work hospit lab oper independ lab caution
data self-report difficult verifi accuraci result said believ
data provid use insight purchas behavior test trend lab
director survey perform molecular test viral load abbott
favor system follow siemen test on-sit use instrument
abbott util instrument siemen doesnt technic
compet mdx viral load test perhap lab director submit respons
qualit test roch market leader viral load test though lab
director note use instrument compani roch player viral
load test follow abbott perhap lack respons roch come
group lab director survey lab director also cite use instrument
biomerieux cepheid
perform molecular test viral load
system use molecular test viral load
note lab director cite multipl system
abbott siemen receiv greatest favor amongst compani expect gain
share viral load molecular test took notabl step
versu prior survey receiv respons relat share gain versu
prior two survey roch abbott current domin market viral load
categori molecular diagnost use measur patient viral load statu
categori hiv hcv hbv said siemen trail abbott
compani overal greatest number posit respons follow
roch posit feedback siemen touch
eas use qualiti servic interestingli roch fare consider better
previou survey believ due experi field flexibl test
platform coba system roch viral load test approv coba
system octob beyond compani respons
fragment compani account remain respons notabl
cepheid receiv respons share compani receiv posit feedback
biomerieux beckman coulter among other
cepheid abbott led respons relat expect share loss beckman
coulter siemen list three time along biomerieux
roch among other neg feedback abbott center old
technolog higher price lower depend
gain share molecular test viral load
lose share molecular test viral load
lab director survey qualit feedback molecular test viral load
comment molecular test viral siemensgain share responseslos share responsegain share responseslos share respons one market leader old technologyw use long time product within line merg aler increas busi place product line anoth system perform test siemen good product way mani platform autom system walkaway lack depend assay meet expect base hear siemen lose share market standard infecti test price certain servic instrument servic friendli compani work autom main analyz easi chemistri test easi use platform avail qualiti test reason cost excel busi motto custom care architect rel easi use assay solid great platform eas use recogn name compani viral load rochegain share responseslos share responsesgain share responseslos share responsesthey take lot test tri put test autom line menu varieti instrument base volum need best class method softwar roch current vendor gain share market new competit brand name new technolog lower cost eas oper broad menu familiar system refer aleregain share responseslos share responsesgain share responseslos share respons provid quicker tat need autom test volum go diff testingmerg uncertain futur test platformmor test perform platforminstru constantli break prevent time test continu gain due broader beckman coultergain share responselos share responsesgain share responselos share responseswel establish vendor provid walk away autom infin system sell well reliabl new instrument good test menu viral testingnot develop assay need current platform solut type test use consid frontier cut edgedo provid test menu cepheid offer much type test diagnost manufacturersgain share responseslos share responsesluminex platform allow growth qiagen move toward autom platform base hear nanospher wide comparison meridian bioscienc diff assay offer barclay holog inc
viral load test type nucleic acid amplif test naat aim
quantifi amount dna rna patient sampl patient manag
abil quantifi nucleic acid import give clinician inform
activ viru today viral load test larg use monitor diseas activ
patient receiv treatment hcv order determin respons
therapi patient track time viral load test importantli viral load
test show patient respond given therapi clinician know
alter treatment level diseas activ measur copi per mililit
copies/ml essenti number viru particl mililit patient
sampl differ patient undergo therapi
hcv common goal receiv treatment simultan test
number copies/ml low enough undetect test
believ viral load test repres annual opportun million global
consist roughli million market hcv million market hiv
million market hbv treatment hbv point limit
approv number therapi treat hiv treat cure hcv
approv creat need viral load test use monitor patient
respons treatment histor market domin roch
abbott howev recent cepheid launch test option europ
current believ roch cover barclay analyst emmanuel papadaki
abbott cover barclay analyst matt taylor hold major
market share viral load test europ said believ
abl leverag panther platform wide success
women health test take share market
human immunodefici viru hiv weaken patient immun system attack
cell import fight infect diseas acquir immunodefici
syndrom aid advanc stage hiv diagnos patient
immun system becom weak fight variou infect two major
type hiv includ common form
diseas affect smaller popul larg western africa cdc guidelin
recommend front line test usual done antigen/antibodi assay
perform diagnos diseas second antibodi differenti
assay confirm type specimen reactiv initi combin assay
nonreact indetermin differenti assay test
qualit fda approv nucleic acid test abbott cepheid
roch qualit test market though display
figur type test repres small fraction overal test
current cure hiv mani treatment allow peopl
live viru extend year common form treatment
antiretrovir therapi art includ combin antiretrovir treatment use
suppress limit progress hiv monitor patient respons art
quantit viral load test use variou point process nation
institut nih recommend test variou interv depend
patient viral load virolog respons treatment describ
world organ similarli believ viral load test
prefer monitor tool patient antiretrovir therapi recommend
test less frequent nih recommend patient undergo art
antigen/antibodycombin immunoassay neg antibodi antibodi differenti antibodi antibodi hiv antibodi indetermin acut neg carefollow diagnosi test perform determin patient level diseas activ art initi modificationtest perform establish baselin order benchmark effect initi subsequ treatment week art initi modificationtest get inform initi respons hiv rna detect repeat everi week viral load suppress copies/ml test everi month thereaft everi six monthsvir load typic measur everi month everi monthsfor patient suppress viral year monitor extend interv treatment failurepati test specif art fail clinic indicatedtest chang scenario creat need test barclay holog inc
receiv viral load test everi month suppress reach
patient switch annual screen
accord estim end million peopl live
world hiv/aid total million estim locat
central africa million locat southern africa
market repres total hiv/aid popul limit
access modern test method though note number diagnost compani
work develop solut improv access test region
estim patient diagnos hiv antiretrovir therapi
 estim million peopl live hiv though
estim one everi eight awar diseas base recent
trend like number patient diagnos live hiv
exceed one million rate hiv diagnos slow success
antiretrovir therapi keep patient aliv longer lead increas hiv
infect popul gilead cover barclay biopharma analyst geoff
meacham report earn call estim roughli patient
diagnos hiv art europ estim roughli peopl
live hiv end estim
diagnos believ percentag patient art europ modestli higher
eu given milder regulatori environ
hepat hcv blood born ill affect liver treat
long-term seriou health effect accord cdc person infect
hcv go develop chronic infect go develop chronic
liver diseas die consequ chronic infect primari
mode transmiss includ share needl use inject drug needlestick injuri
healthcar set birth hcv-infect mother less commonli sex
hcv-infect person number therapeut market today
aim clear hcv patient infect howev vaccin goal
patient undergo sustain virolog respons svr least week
week complet therapi mean longer detect hcv
patient blood
due success hcv drug launch greatest demand treatment
viral load test like histor prior avail
treatment effect low svr rate roughli intoler
side effect direct-act antivir daa emerg allow svr reach
though patient remain pr therapi decemb sovaldi
launch easier administr short treatment window week
high svr rate multipl hcv drug market today
cdc believ svr rate greater
american associ studi liver diseas aasld recommend
patient undergo treatment test quantit hcv rna assay
prior initi treatment four week therapi week follow
complet therapi addit viral load test consid end
treatment week
given
effect new hcv regimen recommend less frequent screen
guidelin screen recommend initi week follow
complet regimen addit favor test guidelin reimburs
quickli follow launch hcv therapeut market today
symptom hcv alway notic larg amount popul
estim infect viru undiagnos cdc estim
adult infect hcv born
peopl believ infect widespread
screen blood suppli happen screen risk-bas
screen hcv implement cdc attempt reduc preval
infect estim infect popul remain
unawar infect cdc implement birth-cohort recommend
one-tim screen patient born follow updat
cdc recommend uspstf aasld also updat guidelin includ
birth-cohort-bas screen updat guidelin includ broader screen
hcv combin effect safer therapeut market hcv infect
peopl diagnos treat often cure caus hcv infect
popul declin
hepat hbv liver infect transmit bodili fluid previous
infect individu transmiss happen sexual contact share drug-
inject equip birth similar hcv acut chronic form
diseas risk acut infect develop chronic infect
put individu risk cirrhosi liver liver cancer chronic infect
adult go develop cirrhosi liver cancer said small portion
adult acut infect becom chronic infect adult chronic infect
common among infant acut infect becom chronic
children age six develop chronic form viru world
health organ estim million chronic infect hbv
concentr heavili weight toward sub-saharan africa east asia
popul estim infect estim less
popul western europ north america infect chronic hbv cdc
estim million peopl chronic hbv
rel hcv earli inning hbv treatment
therapeut market develop chronic hbv though
avail treatment rare cure infect patient gener prescrib
medic life goal treatment slow progress cirrhosi reduc
incid liver cancer improv long-term surviv number compani
process develop therapeut target achiev function cure howev
still multipl year away addit hbv vaccin develop
effect prevent infect diseas
hbv dna measur viral load test gener report intern unit per
ml blood iu/ml gener patient level iu/ml consid
undetect level hbv inact infect patient level greater
aasldwhobaselinexxweek treatmentoptionalcomplet weeksxxcomplet weeksopt barclay holog inc
iu/ml
increas risk diseas progress
recommend march treatment patient chronic hbv
includ commentari around monitor hbv dna level monitor prior
treatment recommend annual screen frequent monitor
patient exce level ul/ml monitor patient treatment test
hbv dna
recommend frequent least everi three month specif
advanc diseas first year treatment adher concern
stop therapi stop treatment recommend test
month first three month everi three month next nine month
aasld guidelin similar guidelin recommend screen
diagnosi regular interv prior concurr therapi increas
interv follow conclus antivir therapi
recommend annual circumst test
viral load market europ histor domin roch
abbott roch first market amplicor monitor test
coba amplicor analyz approv march compani issu
sever upgrad assay releas next coupl year
april roch receiv ce-mark viral load test menu coba
ampliprep/coba taqman includ hcv hbv assay coba
ampliprep system sampl autom platform full autom continu
load coba taqman system pcr-base analyz system
specif design viral load test shortli roch approv abbott
quick join european market releas real-time
real-time hcv test assay launch june juli
compani real-time hbv assay instrument receiv ce-mark juli
follow releas roch first-gener test compani releas second-
gener hbv assay decemb hcv assay januari
recommendationsal patient chronic hepat chb prior post-treatmentminimum annual screeningpati meet criteria antivir therapymor frequent monitor patient fluctuat hbv dna level iu/ml iu/ml well hiv-coinfect personspati treatment follow discontinuationmor frequent monitor everi month person advanc diseas first year treatment adher concern hiv-coinfect person patient follow discontinu treatment barclay holog inc
follow wave approv european market roch abbott
receiv fda approv respect viral load test may roch
beat abbott market coba ampliprep/coba taqman hbv hcv assay
gain fda approv septemb octob respect august
abbott receiv fda approv real-time hbv assay may
compani receiv fda clearanc hcv assay roch second-gener
hcv hbv test gain fda clearanc june septemb march
decemb enter viral load market europ releas
aptima quant dx assay addit compani aptima hcv quant dx
assay aptima hbv quant dx assay earn ce-mark octob decemb
three assay approv compani panther system remind
acquir aptima franchis purchas gen-prob august
decemb roch receiv ce-mark hcv viral load
assay coba compani high-throughput molecular
diagnost system compani hbv test receiv ce-mark march
coba hcv viral load assay receiv fda clearanc octob
hbv viral load assay earn approv decemb coba
improv throughput autom coba
ampliprep/coba taqman system addit new system provid roch greater
opportun menu expans compani number assay
develop regulatori review process three compani viral load assay
hcv hbv approv coba europ system
lower throughput current expans test menu
cepheid current two viral load assay market xpert
xpert hcv viral load assay launch decemb may
respect two test approv europ use compani
technolog competit differenti specif
believ lab purchas decis base number consider includ
cost qualiti workflow addit believ menu option go becom
import consider diagnost compani look expand look
landscap viral load test previous mention believ market primarili
domin abbott roch abbott offer viral load test real-time
system roch offer test coba system well taqman
system full approv europ cepheid still
work round menu cepheid offer test line genexpert
system run aptima viral load assay either panther tigri
anecdot decemb met quest manag team
compani lab futur marlborough explain compani
thought process around implement system quest test avail system
market differ test area test run decid system
make sens cost qualiti effici perspect lab
implement system nationwid
current system mention compani compet
decid compet specif area diseas given compani
complet menu approv europ focu menu point differenti
sexual health test cepheid roch major competitor abbott
roch domin player viral load test interestingli roch
approv viral load sexual health menu test consolid
system today roch approv sexual health menu
coba approv viral load menu coba cepheid
roch abl gain approv test pipelin three compani would
similar menu complet menu first believ compani
first mover advantag take share howev
competit menu complet believ long-term consider focu
cost workflow
 molecular diagnost menu viral load sexual health
full thought
report februari
difficult determin rel cost go
system assay standpoint describ detail
histor low-cost provid coupl effici panther system
compani usual place reagent rental model offer solid valu proposit
said also heard convers lab director roch
gener competit price cepheid believ compani viral load assay
higher end rang think compani abl penetr
lower volum set though believ econom could constrain
higher-volum laboratori also genexpert usual requir capit equip
note histori take market share low cost assay one
best exampl abil step quickli domin molecular
test market hpv screen compani quickli taken domin
posit us market hpv molecular test undergon signific chang
last year transform market highlight rapid growth domin
balanc competit marketplac enter market
acquisit third wave bring compani cervista
hpv test began gain momentum due primarili lower unit
cost lab hsd price vs per kit us price pressur began
shrink overal test market revenu dispar price two kit led
signific reduct qiagen rate addit roch enter market
hpv test genprob earn fda approv late aptima
assay time genprob complet merger two compani
consolid field holog lower price model led rapid share gain
market highlight agreement quest suppli lab
panther tigri instrument molecular test
hpv test ttm market share volum
stack rel competit panther platform arguabl best-
in-class high-throughput custom larg hospit independ lab
throughput test per hour shift rel modest footprint yield
placement count peg around today look requir footprint
length depth lab could fit five panther footprint roch coba
interestingli squar inch basi panther highest throughput given
favor econom reagent rental model custom could simpli place two
instrument next doubl throughput
panther system eight rack assay continu
load abil run four differ assay simultan abbott
assay also abil run four assay simultan roch coba
system abil run three differ test run cepheid genexpert
infin capabl run compani entir test menu
cepheid genexpert infin arguabl easiest use random access
capabl limit hand time said bulki system allow
laboratori achiev effici system hands-on
time genexpert favor minut per assay becom less
favor run volum chart show hands-on time
accord journal clinic microbiolog studi abbott analyz sampl hour
hands-on time base studi present
compar four assay base three metric limit detect lod limit
quantit loq linear rang take-away fda approv assay
rel compar term perform metric base copi per ml
hcv metric base intern unit iu per ml data obtain
packag insert test believ limit quantit linear rang
import metric determin function test said lower
limit detect good indic sensit test
limit detect lod lowest limit copi per ml assay pick
analyt signal reliabl differenti versu signal might
consid background nois result shown base analysi
confid interv versu world organ refer
limit quantit loq loq repres point analyt
detect greater certainti less room error essenti level
cp/ml assay reliabl quantifi amount viral load loq alway
lod
linear rang repres rang assay produc result
repres proport amount concentr analyt
start four test roch lowest limit quantit loq
copi per ml give test expans linear rang holog aptima
assay next best limit quantit copi per ml follow abbott
cepheid copi per ml four test upper limit linear rang
million copi per ml base packag insert assay lowest limit
detect copi per ml
hcv appear favor metric hcv viral load
test compani aptima assay lod plasma serum iu/ml
iu/ml respect addit test linear rang million iu/ml
cepheid competit similar linear rang favor lod
plasma iu/ml said lod serum less favor rel
hbv roch lowest limit detect iu/ml iu/ml
plasma serum sampl respect holog aptima assay next best lod
abbott roch assay linear rang billion iu/ml
copi per mlabbott real-time coba aptima xpert detect quantit unit per ml iu/ml abbott real-time hcvroch coba hcvroch coba hcvholog aptima hcvcepheid xpert hcvlimit detect lod detect lod quantit unit per ml iu/ml abbott real-time hbvroch coba hbvholog aptima hbvlimit detect lod detect lod quantit barclay holog inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
